Free Trial

Cara Therapeutics (CARA) Earnings Date, Estimates & Call Transcripts

Cara Therapeutics logo

Cara Therapeutics Earnings Summary

Cara Therapeutics announced Q2 2024 earnings on August 14, 2024, reporting an EPS of -$13.32, which missed the consensus estimate of -$9.72 by $3.60. Quarterly revenue was reported to be $0.99 million, below the consensus estimate of $1.26 million. Cara Therapeutics currently has a trailing EPS of -$21.01

Latest Q2
Earnings Date
Aug. 14Estimated
Consensus EPS
(Aug. 14)
-$9.72
Actual EPS
(Aug. 14)
-$13.32 Missed By -$3.60
Actual Revenue
(Aug. 14)
$0.99M
Get Cara Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cara Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

CARA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CARA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Cara Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/14/2024Q2 2024-$9.72-$13.32 -$3.60-$0.37$1.26M$0.99M
5/13/2024Q1 2024-$13.68-$20.16 -$6.48-$0.56$2.25M$2.14M
3/4/2024Q4 2023-$20.52-$21.24 -$0.72-$0.59$2.34M$3.00M
11/13/2023Q3 2023-$19.08-$18.72+$0.36-$0.52$8.80M$4.87M
8/7/2023Q2 2023-$20.16-$20.88 -$0.72-$0.58$6.49M$6.93M
5/15/2023Q1 2023-$19.08-$17.64+$1.44-$0.49$5.05M$6.17M


This page (NASDAQ:CARA) was last updated on 5/15/2025 by MarketBeat.com Staff
From Our Partners